# Nervgen Pharma Corp.: overview

NGEN · Nasdaq · CIK 1751912 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ngen.md) · [Financials](/companies/ngen/financials.md) · [Filings](/companies/ngen/filings.md) · [Insiders](/companies/ngen/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

Not reported.

## Last five fiscal years

| Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: |
| Revenue | $ | not reported | not reported |
| Gross margin | % | not reported | not reported |
| Operating margin | % | not reported | not reported |
| Net margin | % | not reported | not reported |
| Diluted EPS | $ per share | [(0.36)](/filings/0001104659-26-037357.md) | [(0.61)](/filings/0001104659-26-037357.md) |
| Free cash flow | $ | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL not reported.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss.
- Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ngen/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Empery Asset Management, LP](/funds/1469336.md) | 2026-06-30 | $8.2m | 4,000,000 |  | New +4,000,000 |
| [Rock Springs Capital Management LP](/funds/1595725.md) | 2026-06-30 | $2.5m | 1,208,231 |  | New +1,208,231 |
| [DAFNA Capital Management LLC](/funds/1389933.md) | 2026-06-30 | $2.2m | 1,050,000 |  | New +1,050,000 |
| [Ghisallo Capital Management LLC](/funds/1825214.md) | 2026-06-30 | $2.1m | 1,000,000 |  | New +1,000,000 |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $1.4m | 678,000 |  | New +678,000 |
| [LMR Partners LLP](/funds/1578621.md) | 2026-06-30 | $1.2m | 600,000 |  | New +600,000 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $898.1k | 435,962 |  | Added +235,603 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $782.2k | 379,726 |  | Added +318,209 |
| [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $559.7k | 271,678 |  | New +271,678 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $557.7k | 270,750 |  | New +270,750 |

## Recent filings

[All 41 filings](/companies/ngen/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-25 | 20:30 ET | [6-K](/filings/0001104659-26-111004.md) | Report of a foreign private issuer, period 2026-09-25 | 0001104659-26-111004 |
| 2026-09-24 | 12:27 ET | [6-K](/filings/0001104659-26-110225.md) | Report of a foreign private issuer, period 2026-09-24 | 0001104659-26-110225 |
| 2026-08-13 | 11:31 ET | [6-K](/filings/0001104659-26-095467.md) | Report of a foreign private issuer, period 2026-08-13 | 0001104659-26-095467 |
| 2026-07-02 | 21:23 ET | [6-K](/filings/0001104659-26-080432.md) | Report of a foreign private issuer, period 2026-07-02 | 0001104659-26-080432 |
| 2026-06-01 | 21:29 ET | [6-K](/filings/0001104659-26-069028.md) | Report of a foreign private issuer, period 2026-06-01 | 0001104659-26-069028 |
| 2026-05-26 | 20:35 ET | [6-K](/filings/0001104659-26-066307.md) | Report of a foreign private issuer, period 2026-05-26 | 0001104659-26-066307 |
| 2026-05-22 | 21:24 ET | [6-K](/filings/0001104659-26-065821.md) | Report of a foreign private issuer, period 2026-05-22 | 0001104659-26-065821 |
| 2026-05-18 | 20:19 ET | [6-K](/filings/0001104659-26-063212.md) | Report of a foreign private issuer, period 2026-05-18 | 0001104659-26-063212 |
| 2026-05-15 | 20:28 ET | [6-K](/filings/0001104659-26-062618.md) | Report of a foreign private issuer, period 2026-05-15 | 0001104659-26-062618 |
| 2026-04-27 | 21:05 ET | [6-K](/filings/0001104659-26-049508.md) | Report of a foreign private issuer, period 2026-04-27 | 0001104659-26-049508 |

## Latest annual report

[Form 40-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-037357.md), filed Mar 31, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1751912
- Tickers: NGEN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.